This inventor holds 1 USPTO granted patent. Top assignee: Carna Health Support Ltd.. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Toshinobu Maki: Innovator in Retinopathy Treatment
Introduction
Toshinobu Maki is a notable inventor based in Fukuoka, Japan. He has made significant contributions to the field of medical treatments, particularly in addressing retinopathy caused by glucose. His innovative approach has led to the development of a unique treatment agent that holds promise for patients suffering from this condition.
Latest Patents
Maki holds a patent for an agent designed to treat and/or ameliorate retinopathy caused by glucose. This agent comprises a sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as its active ingredient. It is formulated to be used at a normal dosage amount or at a lower dosage that does not result in a lowering of blood sugar levels. This innovation represents a significant advancement in the treatment of retinopathy.
Career Highlights
Toshinobu Maki is associated with Carna Health Support Ltd., where he continues to work on innovative solutions in healthcare. His dedication to improving patient outcomes through research and development is evident in his work.
Collaborations
Maki collaborates with esteemed colleagues, including Noriyuki Sonoda and Toyoshi Inoguchi. Their combined expertise contributes to the advancement of medical treatments and innovations.
Conclusion
Toshinobu Maki's contributions to the field of retinopathy treatment highlight his role as an influential inventor. His work not only showcases his innovative spirit but also offers hope for improved healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile